Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Riemsma, Robert P ^a   Bala, Malgorzata M ^b   Wolff, Robert ^a   Kleijnen, Jos ^c  

^a KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLACEBO;

CANCER LOCALIZATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; COLORECTAL CARCINOMA; COLORECTAL LIVER METASTASIS; COMPARATIVE STUDY; EVIDENCE BASED MEDICINE; HEMATOMA; HEPATIC ARTERY; HIGH RISK PATIENT; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; META ANALYSIS; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ARTIFICIAL EMBOLISM; COLORECTAL TUMOR; FEMALE; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; MALE; METASTASIS; METHODOLOGY; VASCULARIZATION;

CHEMOEMBOLIZATION, THERAPEUTIC; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84886809066     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009498.pub3     Document Type: Review

References (60)

1. Hunt TM, Flowerdew AD, Birch SJ, Williams JD, Mullee MA, Taylor I. Prospective randomized controlled trial of hepatic arterial embolisation or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. British Journal of Surgery 1990;77(7):779-82.
2. Australian Safety, Efficacy Register of New Interventional Procedures - Surgical (ASERNIP-S). Radiofrequency ablation of liver tumours (update): A systematic review. ASERNIP-S Report No. 56. Adelaide, South Australia: ASERNIP-S (http://www.surgeons.org/media/17297/RFAupdate.pdf) 2006 (accessed 13 March 2013).
3. Bilchik AJ, Wood TF, Allegra D, Tsioulias GJ, Chung M, Rose DM, et al.Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: A proposed algorithm. Archives of Surgery 2000;135(6):657-64.
4. Bipat S, van Leeuwen MS, Ijzermans JN, Comans EF, Planting AS, Bossuyt PM, et al.Evidence-based guideline on management of colorectal liver metastases in the Netherlands. Netherlands Journal of Medicine 2007;65(1):5-14.
5. Breedis C, Young G. The blood supply of neoplasms in the liver. American Journal of Pathology 1954;30(5):969-77.
6. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.
7. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment for random error risk in conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38:287-98.
8. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291(20):2457-65.
9. Copenhagen Trial Unit. TSA - Trial Sequential Analysis. http://ctu.dk/tsa/ Accessed 13 March 2013.
10. Decadt B, Siriwardena AK. Radiofrequency ablation of liver tumours: systematic review. Lancet Oncology 2004;5:550-60.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34. [PUBMED: 9310563].
13. U.S. Food, Drug Administration. FDA approvals and investigational device exemptions. http://www.fda.gov/ Accessed 13 March 2013.
14. Geoghegan J, Scheele J. Treatment of colorectal metastases. British Journal of Surgery 1999;86(2):145-6.
15. Gluud LL, Thorlund K, Gluud C, Woods L, Harris R, Sterne JA. Correction: reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2008;149(3):219.
16. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 2. Art. No.: LIVER.
17. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985;41:55-68.
18. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Colloboration, 2011. Available from www.cochrane-handbook.org.
19. Hugh TS, Poston GJ. The aetiology and management of hepatic metastases. The Australian and New Zealand Journal of Surgery 1997;67(7):400-9.
20. International Agency for Research on Cancer. Cancer Incidence and Mortality Worldwide in 2008. http://globocan.iarc.fr/ (accessed 13 March 2013).
21. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
22. Jaeger HJ, Mehring UM, Castañeda F, Hasse F, Blumhardt G, Loehlein D, et al.Seguential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Cardiovascular and Interventional Radiology 1996;19(6):388-96.
23. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010;60(5):277-300.
24. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135:982-9.
25. Lau WY. Primary liver tumors. Seminars in Surgical Oncology 2000;19(2):135-44.
26. Llovet JM, Bruix J, for the Barcelona-Clinic Liver Cancer Group. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-42.
27. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Alimentary Pharmacology & Therapeutics 2006;23(11):1535-47.
28. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2].
29. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22:719-48.
30. Markovic S, Gadzijev E, Stabuc B, Croce L, Masutti F, Surlan M. Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. Journal of Hepatology 1998;29:650-9.
31. McCarter MD, Fong Y. Metastatic liver tumours. Seminars in Surgical Oncology 2000;19(2):177-88.
32. McLoughlin JM, Jensen EH, Malafa M. Resection of colorectal liver metastases: current perspectives. Cancer Control 2006;13(1):32-41.
33. Michel S, Sue B, Montpeyroux F, Hachemanne S, Blanc P, Domergue J. Liver resection or transplantation for hepatocellular carcinoma?. Journal of Hepatology 2002;26:1274-80.
34. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
35. National Cancer Institute. SEER Cancer Statistics Review, 1975-2007. http://seer.cancer.gov/csr/1975_2007/ (accessed 13 March 2013).
36. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD004787.pub2].
37. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians 2005;55(2):74-108.
38. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
39. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
40. Riemsma R, Bala M, Wolff R, Kleijnen J. Non-surgical ablation methods for primary malignant liver tumours and liver metastases. Website of the Dutch Health Care Insurance Board (http://www.cvz.nl/binaries/live/cvzinternet/hst_content/nl/documenten/standpunten/2009/sp0905+interventies+levertumoren.pdf) 2009 (accessed 13 March 2013):31-302.
41. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
42. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157:429-38.
43. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
44. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
45. Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anti-Cancer Drugs 2004;15:439-52.
46. Sutherland LM, Williams JAR, Padbury RTA, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors. A systematic review. Archives of Surgery 2006;141:181-90.
47. Taylor I, Bennett R, Sherriff S. The blood supply of colorectal liver metastases. British Journal of Cancer 1978;38(6):749-56.
48. Thorlund K, Devereaux PJ, Wetterslev J, Gyuatt G, Ioannidis JPA, Thabane L, et al.Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. International Journal of Epidemiology 2009;38:276-86.
49. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
50. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual forTrial Sequential Analysis (TSA). http://ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 13 March 2013):1-115.
51. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
52. Vogl TJ, Mack MG, Balzer JO, Engelmann K, Straub R, Eichler K, et al.Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology 2003;229(2):457-64.
53. Vogl TJ, Zangos S, Eichler K, Yakoub D, Nabil M. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion - an update. European Radiology 2007;17(4):1025-34.
54. Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 2009;250(1):281-9.
55. Weiss L, Grundmann E, Torhorst J. Hematogenous metastatic patterns in colonic carcinoma: an analysis of 1441 necropsies. Journal of Pathology 1986;140:195-203.
56. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
57. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in a random-effects meta-analysis. BMC Medical Research Methodology 2009;9:86.
58. World Health Organization. International Clinical Trials Registry Platform (ICTRP). http://www.who.int/ictrp/en/ Accessed 13 March 2013.
59. Wood C, Gillis C, Blumgart L. A retrospective study of patients with liver metastases from colorectal cancer. Clinical Oncology 1976;2:285-8.
60. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601-5.